N@N

Transcept Pharmaceuticals to Report Third Quarter 2012 Financial Results and Host Conference Call on November 12, 2012

^{Published on 2012-11-06 14:01:13 - Market Wire}
 

Transcept Pharmaceuticals to Report Third Quarter 2012 Financial Results and Host... -- POINT RICHMOND, Calif., Nov. 6, 2012 /PRNewswire/ --

[ ]

[ Download image ]

POINT RICHMOND, Calif., Nov. 6, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Monday, November 12, 2012, at 4:30 p.m. Eastern Time to discuss its third quarter 2012 financial results. The conference call will follow the release of the Transcept third quarter 2012 financial results after the close of market that day.

A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at [ www.transcept.com ]. A replay of this webcast will be available on the website shortly after the conclusion of the call through January 30, 2013.

About Transcept

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit [ www.transcept.com ]. For information about Intermezzo, please visit [ www.IntermezzoRx.com ].

Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Sr. Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]

SOURCE Transcept Pharmaceuticals, Inc.